Current HIV/AIDS Reports

, Volume 11, Issue 1, pp 63–71 | Cite as

Antiretroviral Adherence Interventions in Southern Africa: Implications for Using HIV Treatments for Prevention

  • Sarah Dewing
  • Cathy Mathews
  • Geoffrey Fatti
  • Ashraf Grimwood
  • Andrew Boulle
The Science of Prevention (SC Kalichman, Section Editor)


There is concern that the expansion of ART (antiretroviral treatment) programmes to incorporate the use of treatment as prevention (TasP) may be associated with low levels of adherence and retention in care, resulting in the increased spread of drug-resistant HIV. We review research published over the past year that reports on interventions to improve adherence and retention in care in Southern Africa, and discuss these in terms of their potential to support the expansion of ART programmes for TasP. We found eight articles published since January 2012, seven of which were from South Africa. The papers describe innovative models for ART care and adherence support, some of which have the potential to facilitate the ongoing scale- up of treatment programmes for increased coverage and TasP. The extent to which interventions from South Africa can be effectively implemented in other, lower-resource Southern African countries is unclear.


Antiretroviral adherence Retention in care Southern Africa HIV/AIDS HIV Prevention Science of prevention South Africa ART care Treatment as prevention (TasP) TASP 


Papers of interest, published within the annual period of review, have been highlighted • Of importance

  1. 1.
    Williams B, Wood R, Dukay V, et al. Treatment as prevention: preparing the way. J Int AIDS Soc. 2011;14 Suppl 1:S6.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Goga A, Dinh T-H, Dlamini N, et al. Impact of the national prevention of mother to child transmission (PMTCT) program on mother-to-child transmission of HIV (MTCT), South Africa, 2010. In: 6th IAS Conference on Pathogenesis, Treatment and Prevention. Rome, Italy; 2011.Google Scholar
  3. 3.
    Kim MH, Ahmed S, Preidis GA, et al. Low Rates of Mother-to-Child HIV Transmission in a Routine Programmatic Setting in Lilongwe, Malawi. PLoS One. 2013;8:e64979.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Mofenson LM. Technical report: perinatal human immunodeficiency virus testing and prevention of transmission. Committee on Pediatric Aids. Pediatrics. 2000;106:E88.PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339:966–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;9:446–69.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    McNairy ML, Howard AA, El-Sadr WM. Antiretroviral Therapy for Prevention of HIV and Tuberculosis: a Promising Intervention but Not a Panacea. J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S200–7.PubMedCrossRefGoogle Scholar
  10. 10.
    World Health Organization. Antiretroviral treatment as prevention (TasP)of HIV and TB: 2012 Update. Geneva: World Health Organization; 2012.Google Scholar
  11. 11.
    Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–66.PubMedCrossRefGoogle Scholar
  12. 12.
    Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564–73.PubMedCrossRefGoogle Scholar
  13. 13.
    Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21:965–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Barnighausen T, Tanser F, Dabis F, Newell ML. Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence. Curr Opin HIV AIDS. 2012;7:140–50.PubMedCrossRefGoogle Scholar
  16. 16.
    Wandeler G, Keiser O, Pfeiffer K, et al. Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr. 2012;59:e9–e16.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007. AIDS Behav. 2010;24:2263–70.CrossRefGoogle Scholar
  18. 18.
    Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296:679–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Elul B, Basinga P, Nuwagaba-Biribonwoha H, et al. High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. PLoS One. 2013;8:e53586.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr. 2012;61:158–63.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;20:1053–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17:1369–75.PubMedCrossRefGoogle Scholar
  23. 23.
    Thirumurthy H, Siripong N, Vreeman RC, et al. Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting. AIDS. 2012;26:2399–403.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380:1250–8.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Hamers RL, Sigaloff KC, Kityo C, Mugyenyi P, de Wit TF. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS. 2013;8:19–26.PubMedCrossRefGoogle Scholar
  26. 26.
    Nichols BE, Sigaloff KC, Kityo C, et al. Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study. AIDS. 2013. doi:10.1097/01.aids.0000433239.01611.52.PubMedGoogle Scholar
  27. 27.•
    Peltzer K, Ramlagan S, Jones D, et al. Efficacy of a lay health worker led group antiretroviral medication adherence training among non-adherent HIV-positive patients in KwaZulu-Natal, South Africa: results from a randomized trial. SAHARA J. 2012;9:218–26. This randomised trial suggests that lay health workers are as effective as professional clinic staff for providing ARV adherence support. Another significant finding is that an increase in adherence-related information on its own was not enough to impact ARV adherence behaviour..PubMedCrossRefGoogle Scholar
  28. 28.
    Amico KR. Standard of care for antiretroviral therapy adherence and retention in care from the perspective of care providers attending the 5th International Conference on HIV Treatment Adherence. J Int Assoc Physicians AIDS Care (Chic). 2011;10:291–6.CrossRefGoogle Scholar
  29. 29.
    Schneider H, Hlophe H, van Rensburg D. Community health workers and the response to HIV/AIDS in South Africa: tensions and prospects. Health Policy Plan. 2008;23:179–87.PubMedCrossRefGoogle Scholar
  30. 30.
    Dewing S, Mathews C, Schaay N, et al. "It's Important to Take Your Medication Everyday Okay?" An Evaluation of Counselling by Lay Counsellors for ARV Adherence Support in the Western Cape. South Africa: AIDS and Behavior; 2012.Google Scholar
  31. 31.
    Myer L, Zulliger R, Pienaar D. Diversity of patient preparation activities before initiation of antiretroviral therapy in Cape Town, South Africa. Trop Med Int Health. 2012;17:972–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Torpey KE, Kabaso ME, Mutale LN, et al. Adherence support workers: a way to address human resource constraints in antiretroviral treatment programs in the public health setting in Zambia. PLoS One. 2008;3:e2204.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Ritzenthaler R. Delivering antiretroviral therapy in resource-constrained settings: Lessons from Ghana, Kenya and Rwanda. Arlington: Family Health International; 2005.Google Scholar
  34. 34.
    Feldacker C, Johnson D, Hosseinipour M, Phiri S, Tweya H. Who starts? Factors associated with starting antiretroviral therapy among eligible patients in two, public HIV clinics in Lilongwe, Malawi. PLoS One. 2012;7:e50871.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Remien RH, Mellins CA, Robbins RN, et al. Masivukeni: development of a multimedia based antiretroviral therapy adherence intervention for counselors and patients in South Africa. AIDS Behav. 2013;17:1979–91.PubMedCrossRefGoogle Scholar
  36. 36.
    Dean AL, Makin JD, Kydd AS, Biriotti M, Forsyth BW. A pilot study using interactive SMS support groups to prevent mother-to-child HIV transmission in South Africa. J Telemed Telecare. 2012;18:399–403.PubMedCrossRefGoogle Scholar
  37. 37.
    Tirivayi N, Koethe JR, Groot W. Clinic-based food assistance is associated with increased medication adherence among HIV-infected adults on long-term antiretroviral therapy in Zambia. J AIDS Clin Res. 2012;3:171.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Ford N, Mills EJ. Simplified ART delivery models are needed for the next phase of scale up. PLoS Med. 2011;8:e1001060.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.•
    Luque-Fernandez MA, Van Cutsem G, Goemaere E, et al. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One. 2013;8:e56088. This study provides evidence for the effectiveness of a simplified model of care in which the management of ARV treatment is moved out of primary healthcare facilities and in to the community. This model can facilitate the expansion of ART programmes in SSA..PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Medicines Sans Frontiers: ART Adherence Club Report and Toolkit. In: Medicines Sans Frontiers; 2012.Google Scholar
  41. 41.•
    Fatti G, Meintjes G, Shea J, Eley B, Grimwood A. Improved survival and antiretroviral treatment outcomes in adults receiving community-based adherence support: 5-year results from a multicentre cohort study in South Africa. J Acquir Immune Defic Syndr. 2012;61:e50–8. This study shows that the large-scale implementation of a lay health worker delivered adherence support programme in South Africa has been effective in improving adherence outcomes. Strengths of this study include a 5 year follow-up and large sample size from 4 provinces..PubMedCrossRefGoogle Scholar
  42. 42.
    Boyles TH, Wilkinson LS, Leisegang R, Maartens G. Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. PLoS One. 2011;6:e19201.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Kranzer K, Lewis JJ, Ford N, et al. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr. 2010;55:e17–23.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Lyimo RA, de Bruin M, van den Boogaard J, et al. Determinants of antiretroviral therapy adherence in northern Tanzania: a comprehensive picture from the patient perspective. BMC Public Health. 2012;12:716.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34:281–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Eholie SP, Tanon A, Polneau S, et al. Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2007;45:355–8.PubMedGoogle Scholar
  47. 47.
    Uzochukwu BS, Onwujekwe OE, Onoka AC, et al. Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan. 2009;24:189–96.PubMedCrossRefGoogle Scholar
  48. 48.
    Talam NC, Gatongi P, Rotich J, Kimaiyo S. Factors affecting antiretroviral drug adherence among HIV/AIDS adult patients attending HIV/AIDS clinic at Moi Teaching and Referral Hospital, Eldoret, Kenya. East Afr J Public Health. 2008;5:74–8.PubMedGoogle Scholar
  49. 49.
    Byakika-Tusiime J, Crane J, et al. Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav. 2009;13 Suppl 1:82–91.PubMedCrossRefGoogle Scholar
  50. 50.
    Musumari PM, Feldman MD, Techasrivichien T, et al. "If I have nothing to eat, I get angry and push the pills bottle away from me": a qualitative study of patient determinants of adherence to antiretroviral therapy in the Democratic Republic of Congo. AIDS Care. 2013. doi:10.1080/09540121.2013.764391.PubMedGoogle Scholar
  51. 51.
    Senkomago V, Guwatudde D, Breda M, Khoshnood K. Barriers to antiretroviral adherence in HIV-positive patients receiving free medication in Kayunga, Uganda. AIDS Care. 2011;23:1246–53.PubMedCrossRefGoogle Scholar
  52. 52.
    Weiser SD, Tuller DM, Frongillo EA, et al. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS One. 2010;5:e10340.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Siedner MJ, Lankowski A, Tsai AC, et al. GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. AIDS. 2013. doi:10.1097/QAD.0b013e32835fd873.PubMedCentralGoogle Scholar
  54. 54.
    Dahab M, Charalambous S, Hamilton R, et al. "That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health. 2008;8:63.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Miller MM, Ketlhapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health. 2010;15:48–54.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Heffron R, Ngure K, Mugo N, et al. Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr. 2012;61:116–9.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Haire B, Kaldor JM. Ethics of ARV based prevention: treatment-as-prevention and PrEP. Dev World Bioeth. 2013;13:63–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Decroo T, Mondlane V, Dos Santos N, et al. Community ART groups support ART access and retention among HIV-positive dependent children in rural Tete, Mozambique (WEPE720). In: International AIDS Conference. Washington DC; 2012.Google Scholar
  59. 59.
    Dewing S, Mathews C, Cloete A, et al. From research to practice: lay adherence counsellors' fidelity to an evidence-based intervention for promoting adherence to antiretroviral treatment in the Western Cape, South Africa. AIDS Behav. 2013;17:2935–45.PubMedCrossRefGoogle Scholar
  60. 60.
    Mills EJ, Lester R, Ford N. Promoting long term adherence to antiretroviral treatment. BMJ. 2012;344:e4173. doi:10.1136/bmj.e4173.PubMedCrossRefGoogle Scholar
  61. 61.
    Rodrigues R, Shet A, Antony J, et al. Supporting adherence to antiretroviral therapy with mobile phone reminders: results from a cohort in South India. PLoS One. 2012;7:e40723.PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Nash D, Korves C, Saito S, et al. Characteristics of Facilities and Programs Delivering HIV Care and Treatment Services Are Associated with Loss to Follow-up Rates in Programs from 7 Sub-Saharan African Countries. In: 15th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; 2008.Google Scholar
  63. 63.
    Cantrell RA, Sinkala M, Megazinni K, et al. A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2008;49:190–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Sarah Dewing
    • 1
  • Cathy Mathews
    • 1
    • 4
    • 5
  • Geoffrey Fatti
    • 2
  • Ashraf Grimwood
    • 2
  • Andrew Boulle
    • 3
  1. 1.Health Systems Research UnitMedical Research Council of South AfricaTygerbergSouth Africa
  2. 2.Kheth’ImpiloMowbraySouth Africa
  3. 3.School of Public Health and Family Medicine, Faculty of Health SciencesUniversity of Cape TownObservatorySouth Africa
  4. 4.School of Public Health and Family MedicineUniversity of Cape TownCape TownSouth Africa
  5. 5.Department of Psychiatry and Mental HealthUniversity of Cape TownCape TownSouth Africa

Personalised recommendations